Trial record 10 of 12 for: "Lens Disease" | "Loteprednol"
Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01344226|
Recruitment Status : Completed
First Posted : April 29, 2011
Results First Posted : October 22, 2018
Last Update Posted : October 22, 2018
Information provided by (Responsible Party):
Melissa Toyos, Toyos Clinic
|Study Design||Observational Model: Case-Only; Time Perspective: Prospective|
Drug: loteprednol 0.5% ophthalmic solution
|Recruitment Details||Patients in one location of one surgeon's clinic about to undergo cataract surgery were recruited from July 2011 to May 2013.|
|Pre-assignment Details||patients had to be off of steroids for 14 days with no depot steroid injection for 30 days|
Single surgeon, single site study with no randomization or masking. Fewer patients analyzed than anticipated due to competitive recruiting with similar studies.4 screen failures and 8 early terminations.